Advertisement

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond and Kenneth Anderson

Article Information

Citation 
vol. 134 no. 2 123-133
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted February 4, 2019
  • Accepted February 28, 2019
  • Published online July 11, 2019.

Article Versions


Contributors 
  • Joseph Mikhael, 1Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ; 2International Myeloma Foundation, Los Angeles, CA;
  • Paul Richardson, 3Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
  • Saad Z. Usmani, 4Levine Cancer Institute, Charlotte, NC;
  • Noopur Raje, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA;
  • William Bensinger, 6Myeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA;
  • Chatchada Karanes, 7City of Hope National Medical Center, Duarte, CA;
  • Frank Campana, 8Sanofi, Cambridge, MA; and
  • Dheepak Kanagavel, 9Sanofi, Vitry-sur-Seine, France
  • Franck Dubin, 9Sanofi, Vitry-sur-Seine, France
  • Qianying Liu, 8Sanofi, Cambridge, MA; and
  • Dorothée Semiond, 8Sanofi, Cambridge, MA; and
  • Kenneth Anderson, 3Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output